Autolus Therapeutics develops programmed T-cell therapies for cancer, with a focus on next-generation CAR-T approaches. Its lead product, obecabtagene autoleucel (obe-cel), targets CD19-positive B-cell malignancies and is designed for a more controlled safety and persistence profile than earlier CAR-T products. The company serves hematology-oncology patients and clinicians seeking cell therapies for relapsed or refractory blood cancers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 20.9 | — | -47.9 | — |
| Q3 2025 | 21.2 | — | -79.1 | — |
| Q4 2025 | 24.3 | — | -90.3 | — |
| Q1 2026 | 26.2 | — | -71.6 | — |
| Q2 2026 | 45.7 | 118.4% | -39.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Pioneer Bancorp, Inc. (PBFS), Algoma Steel Group Inc. (ASTL), General Fusion Group Ltd. (GFUZ), Columbus McKinnon Corporation (CMCO), indie Semiconductor, Inc. (INDI), NeuroPace, Inc. (NPCE)